First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Relapsed Multiple Myeloma · Refractory Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due May 2025, none posted yet
Counts until it's fixed
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 43 (final count)
- Started
- Sep 26, 2019
- Main results expected
- May 1, 2025
- Fully finished
- May 1, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period
Measured over: Up to 35 Days
Incidence and severity of treatment-emergent adverse events (TEAEs) during REGN5459 treatment period
Measured over: Up to 12 Weeks After the Last Dose
Incidence and severity of adverse events of special interest (AESI) with REGN5459 treatment period
Measured over: Up to 12 Weeks After the Last Dose
Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria
Measured over: Up to Approximately 104 Weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-05-01, no fading
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04083534 · record last updated 2026-05-04 · checked 2026-11-09 15:47 UTC